Skip to main content

Table 1 Demographic details for heart failure patients and healthy controls

From: Evidence for a hyper-reductive redox in a sub-set of heart failure patients

Characteristics of patients Heart failure patients (n = 54) Healthy controls
Hyperreductive
(n = 9)
Hyperoxidative
(n = 23)
Normal redox
(n = 22)
Age in years: mean age (range) 50 (32–75) 58 (34–73) 52 (34–75) 36.35 (18–64)
Sex: n (% male) 9 (100) 23 (100) 21 (95) 27 (64)
Mean height in cm (range) 164 (151.7–177) 163 (152–173) 163 (143–178) 165.8 (148–192)
Mean weight in kg (range) 60 (50–70) 62 (41–75) 63 (38–100) 62.7 (38–89)
Body mass index (kg/m2) (range) 22 (19.5–24.5) 23 (16.4–30.3) 24 (15.2–35.4) 22.9 (16.1–34.6)
Hemodynamics
 Heart rate (no. of times/min) 97 (60–100) 94 (74–121) 96 (70–116) 78 (64–98)
 Mean systolic blood pressure (mmHg) 129 (80–170) 129 (80–180) 125 (90–170) 119 (90–190)
 Mean diastolic blood pressure (mmHg) 79 (60–140) 85 (60–110) 77 (50–110) 76 (50–110)
Comorbidities, %
 DM and DM associated disorders 5 (55) 15 (65) 10 (45)
 Systemic hypertension 3 (33) 5 (22) 6 (27)
 Hypothyroidism 0 4 (17) 1 (4.5)
 Chronic kidney disease 1 (11) 3 (13) 0
 Anaemia 0 2 (7) 2 (9)
 BPH (benign prostatic hyperplasia) 1 (11) 0 1 (4.5)
 Hepatitis 0 0 1 (4.5)
 CVA (cerebrovascular accident) 0 1 (4) 0
 COPD 1 (11) 2 (9) 3 (14)
Cardiac disease pathology, %
 Dilated cardiomyopathy 5 (55) 8 (35) 9 (41)
 Coronary artery disease 2 (22) 10 (43) 10 (45)
 Rheumatic heart disease 1 (11) 0 2 (9)
 Ischemic heart disease 0 1 (4) 1 (4.5)
 Aortoiliac disease 1 (11) 5 (22) 0
 Diastolic dysfunction 10 (43) 7 (32) 8 (89)
 Systolic dysfunction 16 (69.5) 19 (86) 9 (100)
 Biventricular dysfunction 6 (26) 4 (18) 0
 Pulmonary artery hypertension (PAH) 12 (52) 10 (45) 4 (44)
Medication, %*
 Diuretics 5 (55) 20 (87) 18 (82)
 β blockers 4 (44) 12 (52) 12 (54)
 Statins 1 (11) 9 (39) 6 (27)
 ACE inhibitors 3 (33) 10 (43) 10 (45)
 Digitalis glycosides 3 (33) 11 (48) 4 (18)
 Anticoagulant 1 (11) 5 (22) 2 (9)
 (ARB) angiotensin II antagonists 0 5 (22) 1 (4.5)
 Antiplatelet medications 0 5 (22) 3 (14)
  1. * p = 0.005, statistically significant
  2.  p = ns, nonsignificant